(secondQuint)Gemcitabine in Treating Patients With Advanced Colorectal Cancer.

 OBJECTIVES: - Determine the response rate in patients with advanced colorectal cancer treated with gemcitabine.

 - Determine the toxic effects of this drug in these patients.

 - Determine the progression-free survival of patients treated with this drug.

 OUTLINE: This is a multicenter study.

 Patients receive gemcitabine IV continuously over 24 hours on days 1, 8, and 15.

 Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity.

 Patients are followed every 6 months.

 PROJECTED ACCRUAL: A total of 12-41 patients will be accrued for this study within 2 years.

.

 Gemcitabine in Treating Patients With Advanced Colorectal Cancer@highlight

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

 PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating patients who have advanced colorectal cancer.

